ad

3 Enterprise Software Company, Pharmaceuticals Maker and Engineering Consultancy Stocks With a Strong Future Roadmap: Newgen Software Technologies, Ipca Laboratories and Engineers India

Newgen Software Technologies, Ipca Laboratories and Engineers India: ROE of 14.2% to 22.0% and FY22 to FY26 revenue CAGR of 7.9% to 19.4%. Prices as of 16 Nov 2026.


17 Nov 2026 • 2:56 pm

3 Enterprise Software Company, Pharmaceuticals Maker and Engineering Consultancy Stocks With a Strong Future Roadmap: Newgen Software Technologies, Ipca Laboratories and Engineers India

Quick Answer

The three workflow software, drug and design stocks to watch are Newgen Software Technologies, Ipca Laboratories and Engineers India. Their return on equity ranges from 14.2% to 22.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.9% to 19.4%. Engineers India has the highest return on equity at 22.0%, while Newgen Software Technologies has the fastest revenue growth at 19.4% a year. Prices are based on the 16 November 2026 close, and this article is educational, not investment advice.

Workflow software, drug and design stocks offer a focused view of a sector where demand keeps widening. Newgen Software Technologies, Ipca Laboratories and Engineers India cover an enterprise software company, a pharmaceuticals maker and an engineering consultancy.

This list covers three workflow software, drug and design stocks with complete current figures: Newgen Software Technologies, Ipca Laboratories and Engineers India. Every figure comes from the latest reported financials and the 16 November 2026 market close. Companies without complete current figures were left out.

Click Here – Get Free Investment Predictions

What Are Workflow Software, Drug and Design Stocks?

Workflow software, drug and design stocks are listed companies that build software that helps banks and governments manage documents and workflows, make medicines and active ingredients for India and global markets, and offer engineering design and project management for refineries and industry. Their earnings depend on software licences, medicine demand and project awards.

Workflow Software, Drug and Design Stocks at a Glance

Company CMP (Rs) Market Cap (Rs Cr) P/E Industry P/E ROE (%) D/E
Newgen Software Technologies 433.3 6,835 21.8 17.5 18.7 0.02
Ipca Laboratories 1,865.5 46,050 33.5 36.0 14.2 0.10
Engineers India 312.05 15,096 19.2 22.7 22.0 0.01

On valuation, Ipca Laboratories and Engineers India trade at a P/E below the industry P/E, while Newgen Software Technologies trades above it, which reflects the growth the market already expects. Readers comparing workflow software, drug and design stocks should look at return on equity and debt together, since a high return earned with low debt is easier to sustain.

Why Do Workflow Software, Drug and Design Stocks Have a Strong Roadmap in India?

Workflow software, drug and design stocks have a strong roadmap in India because rising use of automation software, steady demand for medicines and a long pipeline of energy and industrial projects keep widening the market for these companies.

  • Enterprise software. Offices move to digital workflows.
  • Medicines. Patients need reliable formulations.
  • Engineering consulting. Refineries need design and management.

Why Newgen Software Technologies Features Among These Workflow Software, Drug and Design Stocks

Among the workflow software, drug and design stocks on this list, Newgen Software Technologies, based in Delhi, offers low-code platforms for content management, process automation and customer engagement to banks, insurers and governments.

The company has a return on equity of 18.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 6,835 crore. The stock trades at a P/E of 21.8, above the industry P/E of 17.5.

Revenue rose from Rs 809 crore in FY22 to Rs 1,641 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 164 crore in FY22 to Rs 301 crore in FY26, which works out to a compound annual growth rate of 16.3%. In the June 2026 quarter, revenue grew 12.3% year on year to Rs 393 crore, while net profit rose 26.3% to Rs 62.8 crore.

Roadmap: Digital transformation at banks and public sector organisations, plus new artificial intelligence features on its platform, widen its addressable market. A growing share of recurring licence and cloud revenue improves predictability.

What to watch: Monitor deal wins in the banking sector and the growth of recurring revenue.

Why Ipca Laboratories Features Among These Workflow Software, Drug and Design Stocks

Among the workflow software, formulations and project consulting shares on this list, Ipca Laboratories is a Mumbai-based pharmaceutical company that makes formulations and active ingredients, with leading brands in pain management, anti-malarials, cardiovascular and anti-infective therapies.

Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%.

In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0.

Roadmap: The company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

What to watch: Monitor the growth of the branded domestic business and the capacity utilisation of its active ingredient plants.

Why Engineers India Features Among These Workflow Software, Drug and Design Stocks

Among the three companies on this list, Engineers India is a public sector engineering consultancy and project company that provides design, project management and construction services to oil, gas, petrochemical, fertiliser and infrastructure clients.

Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%.

The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P/E of 19.2, below the industry P/E of 22.7.

Roadmap: The company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.

What to watch: Monitor order inflow from refinery and petrochemical projects and execution of existing mandates.

Newgen Software Technologies vs Ipca Laboratories vs Engineers India on Key Financials

The table below sets the three workflow software, drug and design stocks side by side on revenue, profit and margin, using reported figures.

Company FY22 Revenue (Rs Cr) FY26 Revenue (Rs Cr) Revenue CAGR (FY22-FY26) FY26 Net Profit (Rs Cr) FY26 Net Margin
Newgen Software Technologies 809 1,641 19.4% 301 18.3%
Ipca Laboratories 5,896 9,821 13.6% 1,191 12.1%
Engineers India 3,043 4,123 7.9% 692 16.8%

Engineers India posts the highest return on equity in this group at 22.0%. Ipca Laboratories has the largest FY26 revenue at Rs 9,821 crore, and Newgen Software Technologies shows the fastest revenue growth with a 19.4% compound annual rate. A useful habit with workflow software, drug and design stocks is to check each new quarterly result against the capacity plans the company described earlier.

Key Risks to Check Before Investing in Workflow Software, Drug and Design Stocks

Every theme carries risks that deserve a check before any decision. For these workflow software, drug and design stocks, the main points are: Long-term workflow software, formulations and project consulting shares holders usually track revenue growth, margins and cash flow side by side rather than relying on a single ratio.

  • Client spending. Technology budgets can vary with global conditions.
  • Regulatory approvals. Plant inspections and approvals can affect supplies.
  • Government spending. Public project funding can shift between periods.

Treat this list as a starting point for research and not as a recommendation. Read the latest results presentation, check the management commentary on order books or capacity plans, and compare each company with its peers before you decide anything.

Use the Univest Stock Screener to filter workflow software, drug and design stocks by market capitalisation, P/E, ROE and growth, and build your own shortlist.

Final Thoughts on Workflow Software, Drug and Design Stocks

Workflow software, drug and design stocks reward patient research into demand, execution and financial strength. Newgen Software Technologies, Ipca Laboratories and Engineers India each have a clear plan to grow. Based on the 16 November 2026 close, Newgen Software Technologies trades at Rs 433.3, Ipca Laboratories at Rs 1,865.5 and Engineers India at Rs 312.05. Valuation matters as much as growth, so compare each company's P/E with its industry P/E before adding any of these workflow software, drug and design stocks to a watchlist.

Download the Univest iOS App or Univest Android App to track workflow software, drug and design stocks, set price alerts and get research-backed stock ideas.

Disclaimer: Data and figures in this article are sourced from publicly available information. These may or may not be accurate. Please verify all data with the official NSE (nseindia.com) and BSE (bseindia.com) websites before making any investment decision. Investments in securities are subject to market risk. This content is for educational purposes only and is not investment advice by Univest (SEBI RA INH000013776).

What are workflow software, drug and design stocks?

Ans. Workflow software, drug and design stocks are listed companies that build software that helps banks and governments manage documents and workflows, make medicines and active ingredients for India and global markets, and offer engineering design and project management for refineries and industry. Their earnings depend on software licences, medicine demand and project awards. This list looks at three of them, Newgen Software Technologies, Ipca Laboratories and Engineers India, using reported FY22 to FY26 financials and the 16 November 2026 closing prices.

Which workflow software, drug and design stocks are covered in this list?

Ans. This list covers Newgen Software Technologies, Ipca Laboratories and Engineers India. Based on the 16 November 2026 close, Newgen Software Technologies traded at Rs 433.3, Ipca Laboratories at Rs 1,865.5 and Engineers India at Rs 312.05. Their return on equity ranges from 14.2% to 22.0%, and their revenue compound annual growth from FY22 to FY26 ranges from 7.9% to 19.4%.

Why do workflow software, drug and design stocks have a strong future roadmap in India?

Ans. Workflow software, drug and design stocks have a strong roadmap in India because rising use of automation software, steady demand for medicines and a long pipeline of energy and industrial projects keep widening the market for these companies. The main drivers are as follows. Enterprise software. Offices move to digital workflows. Medicines. Patients need reliable formulations. Engineering consulting. Refineries need design and management. Together these factors give the companies on this list a visible path for growth over the coming years.

How has Newgen Software Technologies performed financially?

Ans. Revenue rose from Rs 809 crore in FY22 to Rs 1,641 crore in FY26, a compound annual growth rate of 19.4%. Net profit grew from Rs 164 crore in FY22 to Rs 301 crore in FY26, which works out to a compound annual growth rate of 16.3%. In the June 2026 quarter, revenue grew 12.3% year on year to Rs 393 crore, while net profit rose 26.3% to Rs 62.8 crore. The company has a return on equity of 18.7%, a debt to equity ratio of 0.02 and a market capitalisation of Rs 6,835 crore. The stock trades at a P/E of 21.8, above the industry P/E of 17.5. Looking ahead, digital transformation at banks and public sector organisations, plus new artificial intelligence features on its platform, widen its addressable market. A growing share of recurring licence and cloud revenue improves predictability.

How has Ipca Laboratories performed financially?

Ans. Revenue rose from Rs 5,896 crore in FY22 to Rs 9,821 crore in FY26, a compound annual growth rate of 13.6%. Net profit grew from Rs 911 crore in FY22 to Rs 1,191 crore in FY26, which works out to a compound annual growth rate of 6.9%. In the June 2026 quarter, revenue grew 20.2% year on year to Rs 2,813 crore, while net profit rose 80.4% to Rs 423 crore. The company has a return on equity of 14.2%, a debt to equity ratio of 0.10 and a market capitalisation of Rs 46,050 crore. The stock trades at a P/E of 33.5, below the industry P/E of 36.0. Looking ahead, the company has strong domestic brands and a vertically integrated base in active ingredients, which supports quality and cost control. It is expanding its chronic and specialty portfolio and widening its footprint in regulated export markets.

How has Engineers India performed financially?

Ans. Revenue rose from Rs 3,043 crore in FY22 to Rs 4,123 crore in FY26, a compound annual growth rate of 7.9%. Net profit grew from Rs 343 crore in FY22 to Rs 692 crore in FY26, which works out to a compound annual growth rate of 19.2%. The company has a return on equity of 22.0%, a debt to equity ratio of 0.01 and a market capitalisation of Rs 15,096 crore. The stock trades at a P/E of 19.2, below the industry P/E of 22.7. Looking ahead, the company is involved in refinery expansions and new petrochemical projects and is widening its work in green energy, hydrogen and infrastructure. A debt-free balance sheet and a strong order book give it capacity to take on large mandates.

What risks should investors check before buying workflow software, drug and design stocks?

Ans. Investors should check a few risks before buying workflow software, drug and design stocks. Client spending. Technology budgets can vary with global conditions. Regulatory approvals. Plant inspections and approvals can affect supplies. Government spending. Public project funding can shift between periods. Reading the latest results presentation and comparing each company with its peers helps judge how these risks apply to each stock.

Is this list of workflow software, drug and design stocks investment advice?

Ans. No. This article is educational and uses publicly available data as of the 16 November 2026 close. Please verify figures on NSE and BSE, read company filings and consult a SEBI registered adviser before investing. Univest is SEBI registered research analyst INH000013776.

Recent Articles

Note: This blog is for information purpose only. Investments and trading are subject to market risks, read all scheme related documents carefully.

Reviews

user-review-1
user-review-2
user-review-3
user-review-4
user-review-5
ad

Uniresearch Global Pvt Ltd
Research Analyst
SEBI Registration Number — INH000013776
Uniresearch is a subsidiary of Univest Communication Technologies Private Limited

Company Address: Registered Address: Ground Floor, Unitech Commercial Tower 2, Block B, Greenwood City, Unit 1-3, Sector 45, Gurugram, Haryana 122003

Write to us : support@univest.in, compliance@univest.in

Verify on SEBI registry →

RESEARCH ANALYST

Get SEBI Registered
advice on the stocks
trending today.

Get 3 FREE Trade Ideas

+91
for Startups Accelerator 2024

for Startups Accelerator 2024

Trusted by 1Cr Indians

Trusted by 1Cr Indians

Awarded No.1 by Economic Times

Awarded No.1 by Economic Times

GET THE APP

Join 1Cr users today.

SEBI Registered Analyst-backed Picks. Free Demat. One App

  • Free Demat account in under 5 minutes
  • Live market data — Nifty, Sensex, sector insights
  • SEBI Registered analyst-backed stock picks
Get it on Google PlayDownload on the App Store
Stocks:
All|a|b|c|d|e|f|g|h|i|j|k|l|m|n|o|p|q|r|s|t|u|v|w|x|y|z

Copyright 2026 Univest. All rights reserved.
Designed with ❤️ in India

arrow down